Altogether, the results obtained suggest that diseased cats presenting the most aggressive tumor subtypes could take advantage of resorting to immune-targeted therapies (e.g., anti-PD-1, anti-CTLA-4, or anti-VISTA). The gene discussed is PDCD1; the disease is neoplasm.